AN2 Thereapeutics Inc.
13F holders, Q3 2025 (September 30)1holders
0new positions
0sold out
$1.27avg. 13F price*
At the end of Q3 2025, 1 institutions reported holding AN2 Thereapeutics Inc. in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holder was Aldebaran Capital, LLC ($499K).
- Company
- AN2 Thereapeutics Inc.
- CUSIP
- 373261056
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 10,000 shares sold, net −10,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Aldebaran Capital, LLC | 0.46% | Reduce -2.5% | 392,754 | $499K |
"% of holder's portfolio" is AN2 THEREAPEUTICS INC's weight in each manager's 13F, not the share of AN2 Thereapeutics Inc. the manager owns.